EGFR and prostate cancer: Despite these encouraging perspectives, the multiple crosstalk between EGFR, IGF-1R and MET signaling highlighted in preclinical and clinical studies, and herein assessed in castration-tolerant prostate cancer cells, call for concomitant targeting of these three receptors.